CLINDOXYL GEL (logo)
(Clindamycin 1% and benzoyl peroxide 5%)
TOPICAL ACNE THERAPY
CLINDOXYL® Gel (clindamycin phosphate and benzoyl peroxide) ACTION AND CLINICAL PHARMACOLOGY
Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this
compound to the active antibiotic clindamycin. Like other macrolides, clindamycin
inhibits bacterial protein synthesis by binding to the 50S subunit of ribosomes.
Clindamycin in vitro inhibits Propionibacterium acnes.
Bacterial resistance may develop to macrolides, such as clindamycin, especially when
used alone and cross resistance between macrolides has been demonstrated.
Following multiple topical applications of clindamycin phosphate at a concentration
equivalent to 10 mg per mL in an isopropyl alcohol and water solution, very low levels of
clindamycin are present in the serum (0-3 µg/mL) and less than 0.2% of the dose is
The effectiveness of benzoyl peroxide in the treatment of acne vulgaris is primarily
attributable to its antibacterial activity, especially with respect to Propionibacterium acnes, the predominant organism in sebaceous follicles and comedones. The
antibacterial activity of this compound is presumably due to the release of active or free-
radical oxygen capable of oxidizing bacterial proteins. This action, combined with mild
keratolytic effect, is believed to be responsible for its usefulness in acne. P. acnes
resistance has not been reported with benzoyl peroxide. In acne patients treated
topically with benzoyl peroxide, resolution of the acne usually coincides with the
reduction in the level of P. acnes and free fatty acids. Benzoyl peroxide has been shown
to be absorbed by the skin, where it is metabolized to benzoic acid and then excreted
INDICATIONS AND CLINICAL USE
CLINDOXYL Gel (clindamycin phosphate and benzoyl peroxide) is indicated in the
topical treatment of moderate acne vulgaris characterised by the presence of
comedones, papules and pustules. CLINDOXYL Gel is not indicated for the treatment of
CLINDOXYL Gel (clindamycin phosphate and benzoyl peroxide) is contraindicated in
individuals with a history of hypersensitivity to preparations containing clindamycin or
lincomycin, benzoyl peroxide, or any other component of the preparation, a history of
regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. Avoid contact with eyes
and mucous membranes. In the event of accidental contact with sensitive surfaces
(eyes, abraded skin, mucous membranes), bathe with copious amounts of cool tap
Orally and parenterally administered clindamycin has been associated with severe
colitis which may result in patient death. Use of the topical formulation of clindamycin
results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea,
and colitis (including pseudomembranous colitis) have been reported with the use of
Studies indicate that a toxin(s) produced by clostridia is one primary cause of antibiotic-
associated pseudomembranous colitis. The colitis is usually characterized by severe
persistent diarrhea and severe abdominal cramps and may be associated with the
passage of blood and mucous. Endoscopic examination may reveal
pseudomembranous colitis. Stool culture for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.
Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to
several weeks following cessation of oral and parenteral therapy with clindamycin.
Concomitant topical acne treatments are not recommended because a possible
cumulative irritancy effect may occur, especially with peeling, or abrasive agents. If
severe irritation develops, discontinue use and institute appropriate therapy.
Use in Pregnancy Animal reproductive studies have not been performed with benzoyl peroxide. Reproductive studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin ranging from 100 to 600 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to clindamycin. Animal reproduction studies have not been conducted with CLINDOXYL Gel (clindamycin phosphate and benzoyl peroxide). It is not known whether CLINDOXYL Gel can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CLINDOXYL Gel should not be given to a pregnant woman unless the potential benefits to the mother outweigh the possible risks to the fetus. Use in Nursing Mothers It is not known whether benzoyl peroxide or clindamycin are excreted in human milk following the topical use of CLINDOXYL Gel. However, orally and parenterally administered, clindamycin have been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the
drug, taking into account the potential benefits to the mother and the potential risks to the fetus. Pediatric Use Safety and effectiveness in the pediatric population under the age of 12 have not been established. Drug Interactions
Clindamycin has been shown to have neuromuscular blocking properties that may
enhance the action of other neuromuscular blocking agents. Therefore, it should be
used with caution in patients receiving such agents. Benzoyl peroxide inactivates
In controlled clinical trials where a total of 172 patients received CLINDOXYL Gel
(clindamycin phosphate and benzoyl peroxide), the reported adverse events considered
to have a relationship to CLINDOXYL Gel were comprised mainly of reactions at the site
of application such as peeling (16.3%), erythema (7.6%), dryness (7.0%), burning
(2.3%) and pruritus (1.7%). Mild paraesthesia and worsening of acne were noted in one
Orally and parenterally administered clindamycin has been associated with severe
colitis which may end fatally. Cases of diarrhea, bloody diarrhea and colitis (including,
rarely, pseudomembranous colitis) have been infrequently reported as adverse
reactions in patients treated with topical clindamycin (see WARNINGS). Abdominal pain
and gastrointestinal disturbances as well as gram-negative folliculitis have also been
reported in association with the use of topical formulations of clindamycin.
SYMPTOMS AND TREATMENT OF OVERDOSAGE Symptoms
Topically applied clindamycin phosphate formulations can be absorbed in sufficient
amounts to produce systemic effects (see WARNINGS). If medication is applied
excessively, marked redness and peeling may occur. There are no reports of human
ingestion overdosage with CLINDOXYL Gel (clindamycin phosphate and benzoyl
If ingested orally, no specific antidote is available. Simple gastric lavage should be
performed. Treatment should be symptomatic.
DOSAGE AND ADMINISTRATION
CLINDOXYL Gel (clindamycin phosphate and benzoyl peroxide) should be applied
to affected areas once daily before bed time, after the skin has been thoroughly
washed, rinsed with warm water and gently patted dry.
PHARMACEUTICAL INFORMATION Drug Substance
L-threo-α-D-galacto-octopyranoside, methyl 7-chloro- 6, 7, 8-
trideoxy-6-[[ ( 1-methyl-4-propyl-2-pyrrolidinyl) carbonyl ] -
amino ]-1-thio-,2-(dihydrogen phosphate), 2S-trans)-.
Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic
produced by a 7(S)-chloro-substitution of the 7 (R) -hydroxyl group of the parent
antibiotic lincomycin. It occurs as a white to off-white, hygroscopic, crystalline powder. It
is freely soluble in water, slightly soluble in dehydrated alcohol, very slightly soluble in
acetone and practically odourless and has a bitter taste.
Benzoyl peroxide is a white amorphous or granular powder. It loses water rapidly on
exposure to air. Benzoyl peroxide is sparingly soluble in water or alcohol; soluble in
Each gram of CLINDOXYL Gel contains clindamycin phosphate equivalent to 1%
(10 mg) clindamycin in combination with 5% (50 mg) benzoyl peroxide in a base
consisting of carbomer 940, dimethicone, disodium lauryl sulfosuccinate, edetate
disodium, glycerin, hydrated silica, methylparaben, poloxamer, purified water and
Stability and Storage Recommendations
Prior to dispensing, CLINDOXYL Gel should be stored in a cold environment, preferably
a refrigerator between 2° and 8°C. Do not freeze.
To the Pharmacist: Dispense with a 120 day expiration date and specify “Store at room
temperature (15° - 25°C). Keep tube tightly closed. Keep out of the reach of children.”
AVAILABILITY OF DOSAGE FORMS
CLINDOXYL Gel (clindamycin phosphate and benzoyl peroxide) is available in a 30 g
PRODUCT MONOGRAPH AVAILABLE UPON REQUEST
® Registered trade-mark Patent pending STIEFEL CANADA INC.
Montreal, Quebec H4R 1E1 Control No: 089202 2004
Disclaimer: Al information is for knowledge and education purposes and are not used to diagnosis or treat any health condition. For your health matters seek out a “qualified” health professional. On your computer you can use cntrl f to quickly find key words. ORDER YOUR ENZACTA PXP AT WHOLESALE: Sign up as a distributor and save. http://www.pxpteam.com/ellen Sign up for only $99 dollars t
Vitamin B12 and Folate Also known as: Cobalamin; Folic Acid; RBC Folate Formal name: Vitamin B12; Folate Vitamin B12 and folate are primarily ordered to detect deficiencies and to help diagnose the cause of certain anemias. One type of associated anemia is pernicious anemia, an autoimmune disease that affects the absorption of B12. This megaloblastic anemia occurs when the body produces